[Quantities of human papillomavirus 16 E6 mRNA and its relationship with expression of survivin in cervical cancer].
OBJECTIVE
To investigate the quantities of human papillomavirus (HPV) 16 E6 gene and to study its relationship with the expression of survivin in cervical carcinoma.


METHODS
In 148 patients including cervical intraepithelial neoplasia (CIN), cervical carcinoma and chronic cervicitis, the quantities of HPV 16 E6 gene were detected by semiquantitative polymerase chain reaction (PCR); and the expressions of survivin were measured by immunohistochemical streptavidin-biotin peroxidase (SP) assay.


RESULTS
The quantities of HPV 16 E6 gene were 0.3 +/- 0.4, 0.6 +/- 0.4, 1.8 +/- 0.6 and 2.4 +/- 0.6, and expression rates of survivin were 7%, 31%, 63% and 84% respectively in chronic cervicitis, CIN I, CIN II-III and cervical cancer tissues. The quantities of HPV 16 E6 gene and the expressions of survivin tended to increase along with the tumor progression (P < 0.05). The quantities of HPV16 E6 gene and the expressions of survivin of CIN I, II-III or cervical cancer were significantly higher than that of chronic cervicitis or CIN I (P < 0.01). Positive rank correlation between the quantities of HPV16 E6 gene and the expression of survivin was observed in cervical carcinoma (gamma(s) = 0.62, P < 0.05).


CONCLUSIONS
The quantities of HPV16 E6 gene appear to be associated with an increased risk of developing cervical cancer. Survivin overexpression might play an important role in the process of cervical carcinoma.
Liu
Feng-ying
FY
Department of Gynecology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Xu
Xiao-ming
XM
Liu
Yi-zhi
YZ
Wu
Yi-lin
YL
Wu
Ding-wen
DW
D000328:Adult; D000368:Aged; D005260:Female; D052162:Human papillomavirus 16 / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009367:Neoplasm Staging; D009856:Oncogene Proteins, Viral / Q000235:genetics*; D030361:Papillomavirus Infections / Q000378:metabolism / Q000473:pathology* / Q000821:virology; D016133:Polymerase Chain Reaction / Q000379:methods; D012333:RNA, Messenger / Q000235:genetics; D012097:Repressor Proteins / Q000235:genetics*; D000077022:Survivin; D002583:Uterine Cervical Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000821:virology; D002575:Uterine Cervicitis / Q000378:metabolism / Q000473:pathology / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000378:metabolism / Q000473:pathology / Q000821:virology
C107489:BIRC5 protein, human; C068651:E6 protein, Human papillomavirus type 16; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D009856:Oncogene Proteins, Viral; D012333:RNA, Messenger; D012097:Repressor Proteins; D000077022:Survivin